----
Current ValuationThe current P/E ratio is -126.54, below the reasonable range, cheaper than 89.41% of the time in the past 5 years, and the industry ranks 56/58, the industry Median -2.32.
-126.54xP/E
$72.96Stock price
$-0.58Earnings per share
-126.54xP/E
Stock price$72.96Earnings per share$-0.58
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -27.59x
- Typical range
- -60.03x–-10.63x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
010203040
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x40x80x120x160x200x
| Name/Symbol | |||
|---|---|---|---|
LZAGYUSLonza | -388.39x | -- | $53.47B |
CRLUSCharles River Laboratorie | -71.52x | 238.50% | $17.06B |
TEMUSTempus AI | -47.36x | 1.11% | $12.05B |
AVTRUSAvantor | -20.23x | 144.28% | $11.69B |
TXGUS10X Genomics | -126.54x | 108.91% | $9.51B |
BRKRUSBruker | -82.99x | 7.71% | $8.87B |
ADPTUSAdaptive Biotechnologies | -65.66x | 38.37% | $4.19B |
ABCLUSAbcellera Biologics | -23.77x | 36.29% | $3.91B |
FTREUSFortrea | -26.60x | 93.77% | $2.27B |
ALMRUSAlamar Biosciences | -42.46x | 80.56% | $2.11B |
MRVIUSMaravai LifeSciences | -25.44x | 64.44% | $1.97B |
PSNLUSPersonalis | -15.82x | 18.96% | $1.70B |
AZTAUSAzenta | -13.25x | 176.92% | $1.63B |
CYRXUSCryoport | -19.85x | 156.25% | $901.05M |
CTKBUSCytek Biosciences | -9.50x | 33.98% | $765.60M |
PACBUSPacific Biosc California | -5.32x | 75.55% | $699.37M |
DNAUSGinkgo Bioworks | -2.32x | 35.20% | $674.75M |
OABIUSOmniAb | -15.14x | 35.96% | $670.25M |
EVOUSEvotec SE | -2.36x | 385.41% | $539.92M |
TKNOUSAlpha Teknova | -24.25x | 7.81% | $406.62M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
